✦ LIBER ✦

Model protocol to study pharmacogenomics in inflammatory diseases: Human rheumatoid arthritis

✍ Scribed by Mukundan Attur; Clifton O. Bingham III; Mandar Dave; Steven B. Abramson; Ashok R. Amin

Publisher: John Wiley and Sons
Year: 2000
Tongue: English
Weight: 181 KB
Volume: 49
Category: Article
ISSN: 0272-4391
DOI: 10.1002/(sici)1098-2299(200001)49:1<29::aid-ddr5>3.0.co;2-l

No coin nor oath required. For personal study only.

✦ Synopsis

Pharmacogenomics is a revolution in molecular medicine, especially in view of the development of microarray technologies and proteomics to monitor gene and protein expression. The ability to monitor up to 60,000 potential parameters in a clinical setting gives a whole new meaning to 1) toxic effects, 2) side effects, 3) primary and secondary targets, and 4) drug resistance and nonresponders during a clinical trial. Pharmacogenomics may set a new standard to monitor the effects of drugs such as NSAIDS or disease-modifying drugs in diseases such as arthritis. The present article outlines a pharmacogenomics clinical protocol that is in progress, a study that will address some of the above questions. Drug Dev. Res.

📜 SIMILAR VOLUMES

Angiotensin II type 1 receptor as a nove

Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid arthritis: In vivo analyses in rodent models of arthritis and ex vivo analyses in human inflammatory synovitis

✍ A. Price; J. C. Lockhart; W. R. Ferrell; W. Gsell; S. McLean; R. D. Sturrock 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

## Abstract ## Objective Angiotensin II (Ang II) is known to have proinflammatory actions, and Ang II type 1 (AT~1~) receptors are up‐regulated in the rheumatoid synovium, suggesting that this receptor could be a therapeutic target. The purpose of this study was to investigate the antiinflammatory

Interleukin-6 receptor inhibition with t

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

✍ Mark C. Genovese; James D. McKay; Evgeny L. Nasonov; Eduardo F. Mysler; Nilzio A 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 2 views

Reduction in the chondrocyte response to

Reduction in the chondrocyte response to insulin-like growth factor 1 in aging and osteoarthritis: Studies in a non-human primate model of naturally occurring disease

✍ Richard F. Loeser; Gouri Shanker; Cathy S. Carlson; Jean F. Gardin; Brent J. She 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

The use of animal models in the study of

The use of animal models in the study of complex disease: all else is never equal or why do so many human studies fail to replicate animal findings?

✍ Scott M. Williams; Jonathan L. Haines; Jason H. Moore 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB 👁 2 views

Ofatumumab, a human anti-CD20 monoclonal

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

✍ Mikkel Østergaard; Bo Baslund; William Rigby; Bernadette Rojkovich; Christian Jo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 2 views

Phase IIb dose-ranging study of the oral

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

✍ Roy Fleischmann; Maurizio Cutolo; Mark C. Genovese; Eun Bong Lee; Keith S. Kanik 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 3 views